Technical Reports on Generic Drugs Equities -- pSivida, Tetraphase Pharma, Catalyst Pharma, and Galectin Therapeutics

NEW YORK, July 25, 2017 /PRNewswire/ --

If you want a Stock Review on PSDV, TTPH, CPRX, or GALT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. A look at consensus earnings expectations for the Medical sector from the Zacks Earnings Trends report for Q2 earnings season shows that earnings will decline 1% from the year-ago period, while revenues will grow 3.7%. This compares to Q1 earnings growth of 5.5% and revenue growth of 5.7%. In today's pre-market research, DailyStockTracker.com takes note of how the following Generic Drugs stocks have fared over the past few trading sessions: pSivida Corp. (NASDAQ: PSDV), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Galectin Therapeutics Inc. (NASDAQ: GALT). Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at: http://dailystocktracker.com/register/

pSivida 

On Monday, shares in Watertown, Massachusetts headquartered pSivida Corp. saw a decline of 1.46%, ending the day at $1.35. The stock recorded a trading volume of 557,498 shares. The Company's shares are trading below their 200-day moving average by 27.65%. Moreover, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have a Relative Strength Index (RSI) of 29.91.

On June 28^th, 2017, pSivida announced that Kristine Peterson, a seasoned healthcare executive, has been elected to the Company's Board of Directors. Ms. Peterson's election increases the Company's Board of Directors to seven, with six of the Directors being independent. She has extensive pharmaceutical experience, having served as CEO of Valeritas, a publicly-traded, commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes, from 2009 to 2016. PSDV complete research report is just a click away at: http://dailystocktracker.com/registration/?symbol=PSDV

Tetraphase Pharma 

Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. ended the day 9.77% lower at $7.30. A total volume of 1.26 million shares was traded, which was above their three months average volume of 422,570 shares. The stock has surged 81.14% on an YTD basis. The Company's shares are trading above their 200-day moving average by 23.66%. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 46.39.

On July 11^th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $15 per share. The complimentary report on TTPH can be downloaded at: http://dailystocktracker.com/registration/?symbol=TTPH

Catalyst Pharma 

At the close of trading on Monday, shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. finished 4.41% higher at $3.08 with a total trading volume of 846,484 shares. The stock has advanced 12.00% in the last one month, 85.54% over the previous three months, and 193.33% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 23.63% and 92.17%, respectively. Additionally, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 62.20. Sign up for your complimentary research report on CPRX at: http://dailystocktracker.com/registration/?symbol=CPRX

Galectin Therapeutics 

Norcross, Georgia-based Galectin Therapeutics Inc.'s shares recorded a trading volume of 183,433 shares at the end of yesterday's session. The stock closed the day 5.05% lower at $2.07. The Company's shares have skyrocketed 111.27% on an YTD basis. The stock is trading above its 200-day moving average by 18.91%. Additionally, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have an RSI of 33.28. Get free access to your research report on GALT at: http://dailystocktracker.com/registration/?symbol=GALT

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA